PMG Pharmaceuticals

PMV Pharmaceuticals is a clinical-stage precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies that target p53 mutations. The company's lead product candidate, rezatapopt (PC14586), is a first-in-class small molecule designed to correct the misfolding of the p53 Y220C mutant protein, thereby restoring its natural tumor-suppressing function. PMV leverages a proprietary structural biology and chemistry platform to target various p53 mutations, which are present in approximately half of all human cancers. The company is currently advancing rezatapopt through the Phase 2 PYNNACLE clinical trial for patients with advanced solid tumors harboring the p53 Y220C mutation.